OBD Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Oxford BioDynamics (LON: OBD)
›
Oxford BioDynamics (LON: OBD) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 37 employees.
The shares were at 0.1150 GBp on 19 November 2026, down 59.6% over 52 weeks. Its 52-week range is 0.0800 GBp to 0.3400 GBp: the price is 66.2% below the high and 43.8% above the low.
Its market capitalisation is 15.46M GBP.
Oxford BioDynamics reports revenue up 17.0% year over year.
Its debt exceeds its cash by 1.77M GBP, a debt-to-equity ratio of 4.58. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 0.3000 GBp is 160.9% above the current price.